Dialysis Dilemma: How to Reduce Antibiotic-Resistant Infections
"New research reveals a surprising risk factor for Klebsiella pneumoniae in dialysis patients, and what can be done to protect vulnerable individuals."
Antibiotic resistance is a growing global crisis, with bacteria evolving to withstand the drugs designed to kill them. Klebsiella pneumoniae (KP), a common bacterium, is increasingly developing resistance through extended-spectrum β-lactamase (ESBL) production. This makes infections harder to treat, leading to longer hospital stays and increased mortality.
People with end-stage renal disease, who require renal replacement therapy (RRT) such as dialysis, are particularly vulnerable. Uremia, a condition associated with kidney failure, weakens the immune system, making these patients more susceptible to infections. New research highlights the increased risk of antibiotic-resistant KP in this population.
This article breaks down the study's findings and offers practical advice on how to reduce the risk of ESBL-producing KP infections in dialysis patients. We'll explore the factors that contribute to this increased risk and what steps can be taken to protect vulnerable individuals.
Resistance and Dialysis Bloodstream Infections
The CDC notes concerns that antimicrobial approaches may contribute to resistance and may not cover the full range of pathogens that cause bloodstream infections in dialysis patients. The CDC specifically identifies both gram-negative and gram-positive bacteria as potential causes. A study published April 3, 2026, reports comprehensive data on hemodialysis catheter-related bloodstream infections, including clinical presentation, microbiology, resistance patterns, complications, and outcomes.
Resistance Is Predictable—and Preventable
The AMA Journal of Ethics describes antibiotics as arising from an evolutionary arms race among microbes and other ecological competitors, making the emergence of resistance predictable. A review of antimicrobial resistance identifies understanding microbial pathogenesis and resistance, developing new antimicrobials and diagnostic tools, and preventing infections as important strategies. A 2025 chapter likewise names infection prevention, accurate diagnosis, appropriate treatment, and strategic information and innovation as priorities for human health.
Dialysis and Drug Resistance: Understanding the Connection
A recent study published in the Korean Journal of Medical Science investigated the prevalence of ESBL-producing KP in patients undergoing RRT. Researchers retrospectively analyzed data from Seoul Paik Hospital between 2004 and 2011, comparing patients who tested positive for KP with and without ESBL production.
- Compromised Immunity: Uremia, a consequence of kidney failure, impairs immune function, making patients more vulnerable to infections.
- Frequent Healthcare Exposure: Dialysis requires frequent visits to healthcare facilities, increasing the risk of exposure to resistant bacteria.
- Invasive Procedures: The use of central venous catheters for dialysis access provides a direct pathway for bacteria to enter the bloodstream.
- Antibiotic Use: Prior antibiotic use, often necessary in dialysis patients, can disrupt the balance of gut bacteria and promote the growth of resistant strains.
New Reviews and Updated Guidance
A systematic review cited in a November 18, 2025, article examines the potential for new antimicrobial resistance associated with medical devices containing chlorhexidine, minocycline, rifampicin, or combinations of these agents. Separately, the ISPD Catheter-related Infection Recommendations: 2023 Update identifies peritoneal dialysis catheter-related infections as risk factors for catheter loss and peritonitis. The update revised and clarified definitions and classifications for exit-site and tunnel infections.
Documentation and Evidence Gaps
A report on outpatient hemodialysis antibiotic prescribing identifies inadequate medical-record documentation, including missing antibiotic indications, and failure to obtain blood cultures before treatment as barriers to evaluating whether antibiotic doses are appropriate. It also notes that documentation of infection signs and symptoms may be lacking across dialysis facilities. A study of bloodstream infections in chronic hemodialysis patients reports that missing data prevented adjustment for potential confounders including antibiotic regimen, catheter indwelling time, and hemodialysis duration.
Changes Across Measures and Interventions
CDC surveillance reports that the pooled bloodstream infection Standard Infection Ratio decreased by 40% between 2014 and 2019 (p<0.0001; 95% CI [39%, 41%]). In a New Jersey outpatient hemodialysis center, the incidence of all antibiotic-resistant bacteria decreased from 2.04 per 100 patient-months before program interventions to 0.75 after their introduction (p=0.03), then to 0.24 after a behavioral change intervention was added (p<0.01). These are different measures and settings, so their figures should not be treated as directly equivalent.
Protecting Dialysis Patients: A Multifaceted Approach
Combating antibiotic resistance requires a coordinated effort involving healthcare providers, patients, and their families. Simple yet effective measures can significantly reduce the risk of infection and the spread of resistant bacteria.
Stewardship and Facility Assessment
A 2020 report on outpatient hemodialysis prescribing states that inappropriate antibiotic use can cause adverse drug events, including adverse reactions and infections with Clostridioides difficile and antibiotic-resistant bacteria. It also says optimizing antibiotic use can reduce adverse events and improve infection cure rates and patient outcomes. A 2025 article describes using CDC’s ICAR tools with questions specific to hemodialysis to assess a facility’s antibiotic use and provide a framework for setting goals.
Multidrug Resistance and Catheter Infection
A June 2, 2026, article on comprehensive management of hemodialysis catheter-related infections reports that the emergence and dissemination of multidrug-resistant organisms (MDRO) have intensified challenges in preventing and managing hemodialysis catheter-related bloodstream infection (HD-CRBSI). The article frames MDRO as a concern for both prevention and management of HD-CRBSI. Its focus is specifically on catheter-related bloodstream infections in hemodialysis.
The study reinforces the importance of infection control measures in dialysis centers. These include strict hand hygiene practices, the use of gowns, gloves, and face masks by healthcare professionals, and isolating patients with known ESBL-producing KP infections. The distance of bed is also crucial; maintain a distance of 3.6m to avoid any transmission according to recommendation.
While the study's retrospective design has limitations, it provides valuable insights into the increased risk of antibiotic-resistant infections in dialysis patients. By understanding the contributing factors and implementing preventive measures, we can work towards safeguarding this vulnerable population and slowing the spread of antibiotic resistance.